Amy Sam

656 total citations
14 papers, 276 citations indexed

About

Amy Sam is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Amy Sam has authored 14 papers receiving a total of 276 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 8 papers in Pathology and Forensic Medicine and 7 papers in Hematology. Recurrent topics in Amy Sam's work include Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (7 papers) and Multiple Myeloma Research and Treatments (5 papers). Amy Sam is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (7 papers) and Multiple Myeloma Research and Treatments (5 papers). Amy Sam collaborates with scholars based in United States. Amy Sam's co-authors include Stacey Chuma, Kenneth C. Anderson, Diane Warren, Irene M. Ghobrial, Paul G. Richardson, Brianna Harris, Renee Leduc, Meghan Rourke, Steven P. Treon and Jeffrey Matous and has published in prestigious journals such as Journal of Clinical Oncology, Blood and American Journal of Hematology.

In The Last Decade

Amy Sam

14 papers receiving 272 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amy Sam United States	6	232	193	116	79	65	14	276
Elina Vervessou Greece	3	234 1.0×	195 1.0×	75 0.6×	74 0.9×	18 0.3×	4	244
Patricia Severns United States	6	236 1.0×	207 1.1×	84 0.7×	79 1.0×	15 0.2×	13	242
Yiling Yu China	6	122 0.5×	117 0.6×	47 0.4×	44 0.6×	18 0.3×	8	152
Andrew Keezer United States	6	137 0.6×	117 0.6×	47 0.4×	77 1.0×	17 0.3×	14	160
Giorgia Cordisco Italy	7	260 1.1×	106 0.5×	53 0.5×	58 0.7×	57 0.9×	8	292
Vesna Grivcheva‐Panovska North Macedonia	8	402 1.7×	116 0.6×	136 1.2×	114 1.4×	64 1.0×	16	427
Petra Koch Germany	4	389 1.7×	203 1.1×	84 0.7×	78 1.0×	40 0.6×	8	411
Zlatana Pasalic Germany	4	68 0.3×	37 0.2×	77 0.7×	45 0.6×	93 1.4×	6	169
Sean D. Reiff United States	7	135 0.6×	102 0.5×	58 0.5×	32 0.4×	45 0.7×	13	163
Myriam Boudjogra Sweden	2	211 0.9×	150 0.8×	16 0.1×	136 1.7×	31 0.5×	2	222

Countries citing papers authored by Amy Sam

Since Specialization

Citations

This map shows the geographic impact of Amy Sam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Sam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Sam more than expected).

Fields of papers citing papers by Amy Sam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Sam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Sam. The network helps show where Amy Sam may publish in the future.

Co-authorship network of co-authors of Amy Sam

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Sam. A scholar is included among the top collaborators of Amy Sam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Sam. Amy Sam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Ghobrial, Irene M., Wanling Xie, Swaminathan P. Iyer, et al.. (2010). Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. American Journal of Hematology. 85(9). 670–674. 101 indexed citations

Ghobrial, Irene M., Edie Weller, Ravi Vij, et al.. (2010). Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib. Blood. 116(21). 990–990. 5 indexed citations

Ghobrial, Irene M., Fangxin Hong, Swaminathan P. Iyer, et al.. (2010). Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia. Journal of Clinical Oncology. 28(8). 1422–1428. 116 indexed citations

Ghobrial, Irene M., Abdel Kareem Azab, Jacob P. Laubach, et al.. (2010). Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma. Blood. 116(21). 1943–1943. 1 indexed citations

Ghobrial, Irene M., Tiffany Poon, Meghan Rourke, et al.. (2010). Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia. Blood. 116(21). 3952–3952. 9 indexed citations

Leduc, Renee, Marybeth Nelson, Amy Sam, et al.. (2009). A573 Phase I Trial of CCI-779 and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma. Clinical Lymphoma & Myeloma. 9. S86–S86. 1 indexed citations

Ghobrial, Irene M., Fangxin Hong, Swaminathan P. Iyer, et al.. (2009). Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.. Blood. 114(22). 2727–2727. 5 indexed citations

Ghobrial, Irene M., Swaminathan P. Iyer, Ashraf Badros, et al.. (2009). Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia.. Blood. 114(22). 3752–3752. 5 indexed citations

Ghobrial, Irene M., Ravi Vij, Nikhil C. Munshi, et al.. (2009). Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma.. Blood. 114(22). 748–748. 9 indexed citations

10.

Schlossman, R, Stacey Chuma, Renee Leduc, et al.. (2009). A535 Phase II Trial of Bortezomib and Rituximab in Relapsed/Refractory Waldenström Macroglobulinemia. Clinical Lymphoma & Myeloma. 9. S83–S84. 1 indexed citations

11.

Ghobrial, Irene M., Xavier Leleu, Nancy Rubin, et al.. (2008). Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom Macroglobulinemia (WM).. Blood. 112(11). 1010–1010. 2 indexed citations

12.

Ghobrial, Irene M., Jeffrey Matous, Swaminathan P. Iyer, et al.. (2008). Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia. Blood. 112(11). 832–832. 4 indexed citations

13.

Ghobrial, Irene M., Stacey Chuma, Amy Sam, et al.. (2008). Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.. Blood. 112(11). 1011–1011. 6 indexed citations

14.

Ghobrial, Irene M., Nikhil C. Munshi, Robert Schlossman, et al.. (2008). Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma. Blood. 112(11). 3696–3696. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact